Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate.
The bioavailability of the oral iron compound iron(II)-glycine sulfate (ferro sanol duodenal, FSD, 1 x 100 mg Fe/d) was studied in 56 patients with iron deficiency anaemia using a 59Fe-labelling technique and 59Fe-whole-body counting. This technique measures the individual iron loss and allows in patients with substantial blood loss under iron medication a reliable information on the bioavailability of the drug. In all patients, the increased loss of iron (mean 5.8 +/- 4.4 mg/d) was clearly compensated by the iron utilisation (mean: 11.1 +/- 5.6 mg/d) from a daily dosage of 100 mg iron from FSD. A significant increase in the haemoglobin concentration was observed within the monitored treatment period of 6-10 weeks (mean Hb increase from 10.7 +/- 1.7 to 12.1 +/- 1.8 g/dl). FSD has therefore documented a bioavailability of at least 11% from a single daily dose of 100 mg Fe and was effective in the treatment of the anaemia in almost all patients under study.
Nielsen
Peter
P
Institut für Biochemie und Molekularbiologie II: Molekulare Zellbiologie, Zentrum für Experimentelle Medizin, Universitätsklinikum Hamburg-Eppendorf, Germany. nielsen@uke.uni-hamburg.de
Kongi
Rosemarie
R
Buggisch
Peter
P
Fischer
Roland
R
D000328:Adult; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy / Q000378:metabolism*; D001682:Biological Availability; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption; D058085:Iron Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007504:Iron Radioisotopes; D008297:Male; D014915:Whole-Body Counting
D006454:Hemoglobins; D058085:Iron Compounds; D007504:Iron Radioisotopes; C101403:iron-glycine chelate; D005998:Glycine